In the past year,several advancements have been achieved in the treatment of advanced non-small cell lung cancer(NSCLC),particularly in the areas of immunotherapy and targeted therapy.These achievements have provided ...In the past year,several advancements have been achieved in the treatment of advanced non-small cell lung cancer(NSCLC),particularly in the areas of immunotherapy and targeted therapy.These achievements have provided additional options for improving patient outcomes.The 2024 Chinese Society of Clinical Oncology Guidelines for NSCLC(CSCO NSCLC),a key reference for clinical oncologists in China,have incorporated current global research and adapted recommendations for applicability in real-world scenarios in China.This update covers not only patient selection,efficacy,and safety,but also considers economics,and accessibility,with an aim to provide more precise and comprehensive treatment guidance for Chinese oncologists.展开更多
基金supported by the Shanghai Excellent Academic Leader(Grant No.21XD1423200)。
文摘In the past year,several advancements have been achieved in the treatment of advanced non-small cell lung cancer(NSCLC),particularly in the areas of immunotherapy and targeted therapy.These achievements have provided additional options for improving patient outcomes.The 2024 Chinese Society of Clinical Oncology Guidelines for NSCLC(CSCO NSCLC),a key reference for clinical oncologists in China,have incorporated current global research and adapted recommendations for applicability in real-world scenarios in China.This update covers not only patient selection,efficacy,and safety,but also considers economics,and accessibility,with an aim to provide more precise and comprehensive treatment guidance for Chinese oncologists.
